Search results
Results From The WOW.Com Content Network
The COVID-19 vaccination in Singapore is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. Singapore has a very high vaccination rate, with more than 92% of its total population (and ...
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, [2] [33] is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing.
3 February: HSA announced that it had approved Pfizer's Paxlovid COVID-19 treatment tablet for use in Singapore. [14]Two politicians, Minister of State for Communications and Information and National Development Tan Kiat How and Parliamentary Secretary for Culture, Community and Youth and Social and Family Development Eric Chua, have revealed that they tested positive for COVID-19.
The Pfizer-BioNTech COVID-19 vaccine is also approved for full registration. [131] [132] 11 December: It was announced that Singapore had concluded a purchase agreement with AstraZeneca for its Evusheld COVID-19 treatment drug, with the first shipment to arrive at the end of 2021. [133]
Pfizer, one of the world's largest pharmaceutical companies, became a household name in 2020 when it was the first to have its COVID-19 vaccine authorized for use by the FDA. The vaccine came under...
10 December – CP: Singaporeans aged 5 to 11 are now allowed to receive the Pfizer-BioNTech COVID-19 vaccine, the first approved for children. Booster shots are extended to those aged 18 to 29. The Pfizer-BioNTech COVID-19 vaccine is also approved for full registration. [132] [133] 14 December – CP: An expansion of VTL to include Thailand. [134]
Pfizer's vaccine (Comirnaty) and treatment option (Paxlovid) combined for $56 billion in revenue in 2022. Those two products represented just $2.4 billion of Pfizer's $14.9 billion in first ...
Pfizer said it plans to present the data at an upcoming medical meeting and discuss it with global health regulators for a potential approval. The drug is an anti-PD-1 monoclonal antibody, the ...